Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19525976 | 0.90 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25949124 | 0.85 | DDB1 (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26725330 | 0.85 | DDB1 (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26725329 | 0.85 | DDB1 (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768175 | 0.84 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12638348 | 0.84 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15745529 | 0.83 | CRBN (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25477252 | 0.82 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21939264 | 0.82 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12638426 | 0.82 | DDB1 (0.51) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | DDB1 1650/4885CRBN 500/4885IKZF3 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.